Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

EORTC/GIMEMA trial shows combination of GO and chemotherapy provides no benefit for older patients with AML

EORTC/GIMEMA trial shows combination of GO and chemotherapy provides no benefit for older patients with AML

Carcinogens detected in emissions downwind of 'Industrial Heartland'

Carcinogens detected in emissions downwind of 'Industrial Heartland'

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

Bioengineers build novel tool to visualize protein networks from breast cancer cell data

Bioengineers build novel tool to visualize protein networks from breast cancer cell data

Study finds inherited GATA3 gene variation increases risk of developing pediatric leukemia

Study finds inherited GATA3 gene variation increases risk of developing pediatric leukemia

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Scientists identify 127 mutated genes that appear to drive development of tumors in the body

Scientists identify 127 mutated genes that appear to drive development of tumors in the body

UCSD professor receives $6.25M grant to support research on chronic lymphocytic leukemia

UCSD professor receives $6.25M grant to support research on chronic lymphocytic leukemia

UC San Diego researcher awarded grant to advance research on chronic lymphocytic leukemia

UC San Diego researcher awarded grant to advance research on chronic lymphocytic leukemia

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Phase 3 study of idelalisibin reports positive results in CLL patients

Phase 3 study of idelalisibin reports positive results in CLL patients

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

New method for improving cord blood transplant success

New method for improving cord blood transplant success

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.